United States Health

Regeneron (NASDAQ:REGN) expanded its antibody alliance with Sanofi through an agreement covering four long-acting antibody candidates and a $1 billion upfront payment to Regeneron.

Oculis (NASDAQ:OCS) joined the National Multiple Sclerosis Society’s Campaign to End MS as an industry partner focused on advancing research and care related to vision problems in multiple sclerosis.

Pfizer (NYSE:PFE) reported Phase 2 results showing that investigational tilrekimig achieved its primary endpoint by producing statistically significant increases in EASI-75 responses compared with placebo at Week 16 in adults with moderate-to-severe atopic dermatitis.

United Therapeutics (NASDAQ:UTHR) shares rose 13% to $543.99 after a Delaware federal court denied Liquidia’s motion to strike a defense argument in a patent infringement case involving Tyvaso and Yutrepia.

Tiziana Life Sciences (NASDAQ:TLSA) submitted a request to the U.S. Food and Drug Administration for Orphan Drug Designation for intranasal foralumab as a potential treatment for multiple system atrophy (MSA).

Kailera Therapeutics (NASDAQ:KLRA) announced completion of enrollment across three global Phase 3 trials evaluating investigational once-weekly ribupatide injection in people with obesity or overweight.

Jade Biosciences (NASDAQ:JBIO) reported preclinical results for JADE301, an investigational antibody targeting dermatomyositis, at the European Academy of Dermatology and Venereology Congress in Vienna.

Connect Biopharma (NASDAQ:CNTB) reported preliminary Phase 2 results showing that investigational rademikibart reduced treatment failure in adults with acute chronic obstructive pulmonary disease (COPD) exacerbations and type 2 inflammation.

NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary NRx Defense Systems received an initial DARPA prime contract worth $11,177,757.27 to evaluate a treatment approach for major depressive disorder.

Atara Biotherapeutics (NASDAQ:ATRA) announced that partner Pierre Fabre Pharmaceuticals resubmitted the Biologics License Application (BLA) for tabelecleucel to the U.S. Food and Drug Administration for treatment of relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.

Cerenome (NASDAQ:CNSY) reported unaudited third-quarter 2026 gross payer billings of $1.55 million from 222 tests performed by its wholly owned CNSide Diagnostics subsidiary.

Sarepta Therapeutics (NASDAQ:SRPT) presented new clinical data showing ELEVIDYS (delandistrogene moxeparvovec) was associated with functional benefits in older ambulatory patients with Duchenne muscular dystrophy at the World Muscle Society Congress 2026.